Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

REGROTON

CHLORTHALIDONE; RESERPINE

Standard Dose
50MG;0.25MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview REGROTON is listed in Drugs@FDA under application 015103 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient CHLORTHALIDONE; RESERPINE Form and strength TABLET;ORAL - 50MG;0.25MG Sponsor SANOFI AVENTIS US Submission history Latest submission status date: 1988-08-26 00:00:00.

Structured Monograph

Clinical summary

Approval overview REGROTON is listed in Drugs@FDA under application 015103 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient CHLORTHALIDONE; RESERPINE Form and strength TABLET;ORAL - 50MG;0.25MG Sponsor SANOFI AVENTIS US Submission history Latest submission status date: 1988-08-26 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.